News

The European Union patent and trademark office (EPO) has approved the EU patent application no. 08717866.1 (anti-androgen peptides and uses thereof in cancer therapy), which covered the firm’s

ADCT clinical development senior vice president and chief medical officer Dr Jay Feingold said: "We are very pleased with the efficacy and tolerability achieved with our lead hematological

Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care

Risankizumab is a humanized monoclonal antibody, designed to selectively inhibit IL-23 by binding to its p19 subunit. IL-23 is an important cytokine involved in inflammatory processes, and is

The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce

This randomised, open-label, multi-centre trial assessed the efficacy and safety of the combination of Imfinzi (durvalumab) plus tremelimumab, as well as Imfinzi and tremelimumab monotherapies, versus standard-of-care chemotherapy

As per the revised proposal, Takeda offers to pay nearly £49 per each share of Shire in the form of £21.75 in cash and £27.26 in new Takeda

The Phase 2b  Pronto study did not meet its primary or secondary endpoints. A phase 3 Vital Amyloidosis study is also being discontinued based on futility analysis. AL amyloidosis is a

Zymeworks president & CEO Ali Tehrani said: “The team at Celgene has made excellent progress developing bispecific and multifunctional therapeutic candidates built on our industry-leading Azymetric platform and